Launch Date
04/22/2022
Credit Amount
0.50 Hours
Credit Expires
04/22/2023
Clinicians may be familiar with current guideline recommendations for the use of traditional CRSwNP therapies (e.g., corticosteroids, sinosurgery). However, new global guidance has been issued from EUFOREA for use of biologics in the management of uncontrolled CRSwNP. These guidelines include a practical algorithm to define type 2 inflammation in order to enable an informed and shared decision-making process for the selection of biologic agents. Additionally, both general and specialist HCPs report uncertainty and variability regarding the best management of chronic rhinosinusitis.
In part 2 of this CMEO Snack series, join Dr. Han and Dr. Hopkins as they translate the updated guideline recommendations and discuss how to implement the suggestions into clinically meaningful changes in practice. Translation of the guidance by experts in the field will assist in a better understanding and application of the guidance to clinical practice.
At the end of this CME/CE activity, participants should be able to:
Translate updated guideline recommendations to treatment decisions for the management of uncontrolled CRSwNP.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Han reports the following financial relationships: Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme
Dr. Han reports the following financial relationships: Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme
Dr. Hopkins reports the following financial relationships: Advisory Board: GlaxoSmithKline. Consultant: AstraZeneca and Sanofi Genzyme. Speakers Bureau: Intersect ENT, Inc.; Mylan Pharmaceuticals, Inc.; and Olympus Corporation
Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
Janan Sarwar, PharmD (planning committee)
Evan Luberger (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-059-H01-P.
Call us at 877.CME.PROS (877.263.7767).
SN-162-042222-90